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Abstract   
Cognitive behavioral therapy (CBT) is efficacious for panic disorder with agoraphobia (PD/A). 
Nevertheless, the active ingredients of treatment and the mechanisms through which CBT achieves its 
effects remain largely unknown. The mechanisms of action in CBT (MAC) study was established to 
investigate these questions in 369 patients diagnosed with PD/A. The MAC study utilized a multi-
center, randomized controlled design, with two active treatment conditions in which the administration 
of exposure was varied, and a wait-list control group. The special feature of MAC is the way in which 
imbedded experimental, psychophysiological, and neurobiological paradigms were included to 
elucidate therapeutic and psychopathological processes. This paper describes the aims and goals of the 
MAC study and the methods utilized to achieve them. All aspects of the research design (e.g., 
assessments, treatment, experimental procedures) were implemented so as to facilitate the detection of 
active therapeutic components, and the mediators and moderators of therapeutic change. To this end, 
clinical, behavioral, physiological, experimental, and genetic data were collected and will be 
integrated.  
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Theoretical background  
 
Cognitive behavioral therapy (CBT) across its many variations is efficacious for a wide range 
of mental disorders, with particularly strong effects for panic disorder and agoraphobia 
(PD/A) [5, 33, 36]. Despite the clear empirical support for CBT, numerous issues remain 
unclear. Primary among these is determining the mechanisms of action that lead to 
meaningful therapeutic change. The significance of identifying the active ingredients and 
mechanisms involved in the therapeutic process is manifold, with direct implications for the 
delivery of treatment, prediction of treatment response, understanding of factors that maintain 
therapeutic effects, and revealing possibilities for improvement of CBT as a 
psychotherapeutic method. Indeed, identification of the most relevant active ingredients and 
the core mechanisms involved in therapeutic improvement has implications for the definition 
of CBT itself.  
 
As evidenced by numerous theoretical debates, the time is ripe to better understand what CBT 
is, what it changes, and how those changes are achieved [4, 30, 46]. To obtain such an 
understanding, a research design is needed that goes a step beyond those used in traditional 
efficacy trials. This means that an understanding of how CBT works necessitates the 
assessment of numerous factors not normally considered, and the more factors considered, the 
larger the required sample size. The mechanisms of action (MAC) study for panic and 
agoraphobia was established as a starting point to address these questions using a whole range 
of clinical and basic methods.  
 
At the molar level (i.e., variables and constructs defined at a higher level of abstraction 
relative to lower-level molecular variables and constructs) hypotheses regarding possible 
mechanisms of therapeutic action abound [43]. They range from change in self-efficacy, to 
changes in “cognitive” constellations, to more precise hypotheses derived from learning 
theory such as habituation and extinction [15, 16, 36]. Fewer hypotheses exist at the 
molecular level, in part because the identification of therapeutic processes has seldom been a 
part of this research tradition. That said, preliminary research has implicated neural networks 
such as the so-called “fear circuitry” [18, 26, 27], the influence of functional genetic 
polymorphisms including the gene coding for the serotonin transporter protein [22, 23, 35], 
and psychophysiological processes [37]. Embedded in a large state-of-the art research 
platform, the MAC specifically targets molar variables in the form of objective and subjective 
ratings, molecular genetic variables, and those in-between of physiological measurements and 
functional magnetic resonance imaging (fMRI) approaches. Contrary to previous research, 
however, the MAC was structured such that the large number of dynamically interacting 
variables and levels can begin to be unraveled through the identification of salient processes 
that moderate and mediate treatment outcome. Emphasis in the first phase of the program was 
put upon the identification of active ingredients of CBT most likely involved in promoting 
therapeutic change.  
 
Primary candidates for salient variables include the frequency, intensity, and type of 
administration of exposure in vivo exercises (i.e., under therapists guidance versus 
administration of intense cognitive exercises intended to induce behavioral change). 
Consistent with the available evidence, both variants of CBT are hypothesized to result in 
alterations of patients’ cognitive appraisals and a reduction of panic and agoraphobia 
symptoms. Hypothesized differences between these two CBT variants relate to the speed, 
persuasiveness, and stability of changes as well as expectations that distal and proximal 
patient characteristics will be associated with differential treatment outcomes. Thus, the first 
aim of the MAC is to examine to what degree CBT with explicit exposure in vivo under 
therapist guidance outside the therapy room results in different changes as compared to a CBT 
variant where the therapist attempts to implement the same exercises without leaving the 
therapy room with the patient for the actual in vivo exposure exercises. Following an 
examination of the overall effectiveness of these two CBT variants (active tx) versus a wait 
list control group, the second phase of the research program will produce finer-grained 
analyses of putative mechanisms of change and the identification of predictors for sustained 
response and remission.  
 
With these goals in mind, the MAC established a standardized treatment protocol and manual 
[34] utilized with all patients as a spring board from which to determine how therapeutic 
processes and outcomes are associated. In particular, the MAC targeted (a) learning processes 
involved in the startle reaction, anticipatory anxiety, and associated autonomic responses; (b) 
the processing of anxiety-relevant stimuli using paradigms of exteroceptive and interoceptive 
perception and conditioning/extinction; and (c) genetic variations.  
 
Given that the MAC represents one of the first attempts to bridge traditionally isolated areas 
of research, it is worthwhile and necessary to examine the methods utilized and, en route, to 
clarify terms. It is to this task that we now turn our attention beginning with a description of 
the clinical trial concluding with experimental paradigms.  
 
 
 
 
Methods of the overarching clinical trial  
 
Research design  
 
The MAC is a randomized, multicenter, clinical treatment outcome study with 369 outpatients 
who met DSM-IV criteria for panic disorder and agoraphobia. The study design was 
structured so that measures of treatment course and outcome could be related to specific 
treatment components. All patients were randomized to two active CBT treatment variants 
and a wait-list control group (WL). The distinguishing feature between otherwise identical 
CBT variants dealt with the administration of the exposure in vivo. The first active CBT 
condition included some sessions in which the therapist provided active guidance in exposure 
outside the therapy room (therapist guided exposure T+), whereas in the second active CBT 
condition the therapist was confined to the therapy room (no therapist guided T-).  
 
Procedure  
 
Patient recruitment, inclusion and exclusion criteria  
 
Eight treatment centers in Germany participated (Aachen, Berlin-Adlershof, Berlin-Charité, 
Bremen, Dresden, Greifswald, Münster, Würzburg). Participants were recruited from ongoing 
clinical mental health care (i.e., 3 psychiatric clinics and 5 clinical psychological outpatient 
centers), physician referral (e.g., primary care physicians, neurologists, psychiatrists, 
cardiologists), and via additional advertisements in various media outlets (e.g., newspapers, 
internet, television). Participants who screened positive for the inclusion criteria were given 
an appointment to obtain written informed consent. Those who agreed to partake in the study 
scheduled a diagnostic appointment to determine whether all inclusionary criteria were met.  
 
Inclusion criteria consisted of: (a) a current primary diagnosis of panic disorder and 
agoraphobia (PD/A) (as defined by the criteria of the diagnostic and statistical manual, fourth 
revision/text revision (DSM-IV-TR) [2] validated by a standardized computer-administered 
personal Composite International Diagnostic Interview (CAPI-WHO-CIDI; DIAX-CIDI 
version [47]); (b) a clinical interview score C18 on the structured interview guide for the 
Hamilton anxiety scale (SIGH-A [44] in anxiety and depression); (c) a score C4 on the 
clinical global impressions scale (CGI) [28]; (d) age 18–65 years; (e) ability and availability 
to regularly attend treatment sessions. The flow of patients into the study can be seen in Fig. 
1. Nineteen patients from the WL were re-randomized to one of the active treatment 
conditions following the waitlist period. These patients met all inclusion criteria at the time of 
re-randomization.  
 
Compared to previous studies, exclusion criteria were minimal to allow for the inclusion of 
patients with comorbid conditions commonly seen in daily practice. Exclusion criteria were 
(a) comorbid DSM-IV-TR psychotic or bipolar I disorder; (b) current alcohol 
dependence/current abuse or dependence for benzodiazepine and other psychoactive 
substances; (c) current suicidal intent, (d) borderline personality disorder, (e) concurrent 
ongoing psychotherapeutic or psychopharmacological treatment for PD/A or another mental 
disorder; (f) antidepressant or anxiolytic pharmacotherapy; (g) physician-verified 
contraindications of exposure-based CBT (i.e., severe cardiovascular, renal, and neurological 
diseases). The frequencies with which patients were not allocated to treatment because of 
these inclusion and exclusion criteria are listed in Table 1. As can be seen in Table 1, most 
patients were excluded because their scores on the clinical rating scales were too low, thus 
suggesting that the patients in the MAC are relatively severely affected.  
Sample characteristics  
 
Table 2 describes the sociodemographic characteristics of the 369 patients enrolled. The 
sample consisted overwhelmingly of patients with psychiatric comorbid conditions, with a 
mean of 3.5 comorbid diagnoses. Only 7.9% had no other diagnoses, whereas additional 
diagnoses were present as follows: 1–2 comorbid diagnoses (44.7%), 3–4 (33.9%), and 5 or 
more comorbid diagnoses (13.6%). The most frequent comorbid diagnoses were: specific 
phobias (69.4%), social phobia (41.7%), major depression (35.2%), harmful use of alcohol 
(37.4%), pain disorder (34.2%), and generalized anxiety disorder (20.3%).  
 
Assessment  
 
Assessments occurred at five primary time points chosen to capture changes in putative active 
ingredients in the treatment process (see Table 3): diagnostic (before inclusion), baseline 
(before treatment), intermediate (after the fourth session), post (immediately following 
treatment), and follow-up (6 months after the end of treatment). Each treatment session 
included a number of additional assessments, partly embedded within the therapy itself and 
tightly linked to add on studies. A description of the utilized measures can be seen in 
„Appendix”. Patients in the WL group took part in all assessments from baseline to post-
treatment.  
 
Primary outcome parameters targeted domains of global anxiety and panic/agoraphobic-
specific symptomatology [31]. These were assessed using both interview-rated outcome 
measures [SIGH-A total score (range 0–56) and the CGI (range 1–7)] and questionnaires 
completed by the patients assessing panic attacks [panic and agoraphobic scale (PAS)—mean 
number of panic attacks in the past week (subscale range 0–4)] and agoraphobic avoidance 
[mobility inventory original version (MI)]—mean of the alone subscale (range 1–5)]. 
Secondary outcomes were included to assess additional domains and answer secondary 
questions (see Table 3; Appendix). Among these, several behavioral measures (i.e., the 
amount of time the patient remained in the behavioral avoidance test, the frequency of 
exposures, duration of exposures, and distress experienced during exposures) were recorded.  
 
Patients additionally completed self-monitoring forms throughout the treatment, especially 
before and after each exposure exercise. Prior to the exposure patients recorded information 
about the situation and anticipatory anxiety. Following the exposure, patients recorded the 
course of anxiety during the exercise, any use of safety behaviors, and their subjective 
conclusions regarding the exercise. Therapists separately recorded all safety behaviors utilized 
by the patient during the exercise.  
 
Data collection and database  
 
Assessments were directly entered by patients into an internet-based computer interface. 
Missing data were minimal due to the use of programmed algorithms that informed the 
interviewer and the patient of any missing data and prompted completion before continuing 
(around 2% across all items and assessments). Patients were trained by their therapist in the 
use of the computer program. All data was linked with the corresponding login password so 
that every change of the database was time-stamped and could be tracked. The database was 
saved at a central data coordinating center (study coordination center; KKS Dresden) that also 
insured data security. The database was checked regularly and the time of entry was compared 
against the scheduled entry time. Therapists and clinical directors of each center received 
regular feedback about the quality and timeliness of data for each of their patients.   
 
Treatment  
 
Treatment procedure  
 
Therapy consisted of 12 individual sessions conducted over approximately 8 weeks. The 
therapy was implemented twice weekly with each session lasting approximately 100 min. The 
therapy was based on established manuals [15] previously evaluated as effective for patients 
with PD/A in several clinical trials [8] and developments in exposure-based CBT [6, 38, 42]. 
Based on these existing manual components a study manual—optimized for the study 
rationale and for component analyses—was written by experts for exposure therapy [34]. The 
manual focused on a clear differentiation between different techniques of exposure therapy as 
a basis for a better understanding of the mechanisms of action as well as an optimal separation 
between T+ and T-. It is again important to note that both active therapy variants T+ and T- 
contained exactly the same ingredients, were of identical duration, and differed only in the 
manner in which the exposure was implemented in vivo (therapist guided, supervised, and 
intensified vs. no therapist present during in vivo exposure exercises).  
 
The manual was highly structured and detailed to minimize between-therapist variability. 
Details were conveyed in multiple levels (e.g., session overview, guiding principles, session 
take-home message, aims, session-specific exercises and forms). It included detailed 
descriptions of each procedure, provided sample dialogues, and anticipated typical problems 
with guidance for solutions. Figure 2 highlights the main components of each session.  
 
The first treatment phase (sessions 1–5) was identical in both conditions (e.g., establishing 
therapeutic rapport, psycho-education, self-monitoring, functional analysis, interoceptive 
exposure). Only sessions 6–8 and 10–11 differed between the groups with respect to the 
implementation of exposure (T+ and T-). Although the T-condition discussed various aspects 
of exposure including barriers to effective implementation, no formal cognitive restructuring 
or disputation of thought content was implemented. Patients in both treatment groups were 
instructed to engage in three standardized exposure exercises (bus, department store, forest) 
followed by two individualized situations. In the T+ condition, exercises were carried out 
during the session with the therapist present. Prior to the next session, the patient was 
instructed to repeat this exposure exercise two more times. Patients in the T- group were 
instructed to complete three self-exposures between these sessions, thus holding the assigned 
number of exposure exercises constant between the two conditions. Quantification of all 
initiated exposures, whether assigned or not, were recorded at the next session in terms of the 
frequency, duration and experienced distress of all exposures. All self-exposures were 
reviewed in the following session in both conditions.  
 
In both active treatment conditions, two booster sessions (sessions 13–14) were conducted. 
These sessions reviewed progress, addressed avoidance behavior—especially in stressful 
situations—and discussed additional exposure exercises that the patient could practice.  
 
Manual training, certification of therapists, and supervision  
 
All therapists were trained by experts in exposure-based CBT for P/A. All therapists were 
qualified at least at the level of advanced graduate student status in clinical psychology. 
Content of the manual was trained over a 3-day intensive and interactive course followed by a 
recorded role-play graded by experts. Therapists were only allowed to see study patients after 
passing the role-play examination. Of 89 therapists trained in these procedures, 75 were 
certified as study therapists.  
 
During this psychotherapy study, all therapists were involved in weekly manual specific 
supervision in their respective study center. Supervision was supplanted with a weekly 
telephone conference involving all centers in which problems with the manual and the study 
protocol were discussed.  
 
Therapy integrity  
 
All sessions were recorded on video cassettes or DVD. All violations of the protocol were 
documented and reported to the study coordination centers. Therapy integrity was assessed by 
independent raters. Over 15% of all sessions (n = 724/4,214 = 17.2%) were randomly selected 
and analyzed using the therapist adherence and competence rating scale for panic disorder and 
agoraphobia [24]. All raters took part in a two day training procedure and passed a 
qualification exam. The exam consisted of two videos, each of which had to be rated within 
one point of the expert rating on each item.  
 
Core experimental components  
 
Behavioral avoidance test  
 
A behavioral avoidance test (BAT; darkroom paradigm) was executed at pre, intermediate, 
post, and follow-up in all patients to explore changes in symptom reports of avoidance 
behavior and physiological responding during anticipation (sitting 10 min in front of the 
cabinet) and exposure (10 min) in a narrow (120 9 75 cm) and dark room. The administration 
of this test aims to explore the mechanism of innervations at the behavioral and 
psychophysiological level [1]. Skin conductance and heart rate were obtained as measures of 
autonomic arousal while startle responses to acoustic probes (surface electromyography 
recordings over the left orbicularis oculi muscle) were measured as an index of subcortically 
mediated defense mobilization. Prior to therapy, 68% of all patients stayed in the dark room 
for the entire 10 min. 20% of the patients, however, escaped from the dark room with an 
average duration of 4 min. 12% of the patients refused to enter the dark and were thus 
categorized as avoiders. Overall, patients experienced 45 panic attacks within the dark room, 
with no differences between escapers and non-escapers. Overall, the heart rate was increased 
during exposure for escapers compared to non-escapers suggesting that increased 
physiological arousal might predict behavioral avoidance. On the other hand, those patients in 
the non-escaper group who reported comparably high levels of anxiety during exposure as the 
escapers also had significantly increased heart rates but did not leave the room.  
 
Psychophysiological subtypes  
 
In order to explore the value of respiratory and vestibular panic subtypes in the overall study, 
a subset of patients underwent two biological challenges [3]. In order to measure vestibular 
sensitivity, different visual flow stimuli were presented through a head-mounted display, 
thereby inducing a conflict between visual input and somatosensory information [32]. Anxiety 
and dizziness were assessed repeatedly by means of self-reports, while resultant body sway 
was measured continuously with a force plate that individuals stood on. In order to measure 
respiratory sensitivity, we measured responses to a hypoxic (12% O2) and a hypercapnic 
(7.5% CO2) laboratory challenge while measuring tidal volume, respiratory rate, the end-tidal 
CO2 concentration in the exhaled air, anxiety, and panic symptoms. The observed 
physiological reactions will be related to previously identified latent class factors [3] with the 
aim of clarifying the impact of differential symptomatology on treatment efficacy, and to 
determine to what extent treatment should be tailored to these subtypes.  
 
Fear circuitry mechanisms  
 
Using three paradigms (aversive conditioning, interoception vs. exteroception, and 
anticipation of panic-relevant stimuli) before and after treatment, this project examines 
changes in the fear circuitry mechanisms associated with panic disorder and agoraphobia and 
potential activation pattern of treatment response [10].  
 
Genetic variation and prediction  
 
Functional risk polymorphisms for panic disorder such as those of the serotonin transporter, 
the monoamine oxidase or catecholamine-o-methyltransferase genes [19] or for novel genetic 
risk polymorphisms derived from animal models such as a neuropeptide S receptor gene 
polymorphism will be explored. Intermediate phenotypes for panic disorder will be examined 
under the premise that these correlate better with biological parameters like genetic variations. 
For example, heart rate in the BAT will be correlated to a functional polymorphism in the 
serotonin 1A receptor gene to determine whether this genetic variant exerts some of its effect 
via modulating vegetative parameters [21]. Additionally, genome-wide approaches will be 
utilized to define hitherto unknown genetic variants which increase the risk for panic disorder 
and/or influencing the therapeutic response to cognitive behavioral therapy.  
 
 
Conclusion  
 
MAC is a state-of-the-art collaborative and interdisciplinary research platform from which the 
mechanisms of therapeutic action in exposure-based CBT for patients with panic disorder and 
agoraphobia will be investigated. MAC promises to offer insights about a range of issues. The 
data will provide information about how variations in exposure-based CBT differentially 
affect a range of behavioral, cognitive, affective, and physiological outcomes. Necessary, 
salient, inactive, and even iatrogenic components can be identified and related to courses of 
symptomatology, maintenance of therapeutic gains, and relapse. In turn, the dynamic 
relationship between these results and molecular variables as well as variables from a 
systems-neuroscientific approach will be examined with the prospect of identifying moderator 
and mediator variables. Finally, MAC will generate hypotheses that will lead to a number of 
experiments that will focus on specific mechanisms of disease and therapeutic action. 
Evidence is already emerging that the sum total of the findings expected from MAC will 
significantly contribute to our understanding of the mechanisms of action in CBT.    
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